Pfizer pledges $100M for antimicrobial resistance

By The Science Advisory Board staff writers

Pfizer has pledged $100 million to the Antimicrobial Resistance (AMR) Action Fund to address the need for new antibiotics due to the rapid rise of antibiotic-resistant infections.

The AMR Action Fund is a collaboration among over 40 biopharmaceutical companies with the goal of bringing two to four new antibiotics to the clinic by 2030 through partnerships with pharmaceutical companies, philanthropies, development banks, and multilateral organizations.

The new commitment builds on Pfizer's existing work to address AMR through the development of vaccines that reduce the need for antibiotics, active research in anti-infectives, and work with clinical partners to close gaps in infectious disease treatments. The company also manages Atlas, a public access platform for antifungal and antibacterial resistance data.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?